This segment focuses on the research, development, and clinical trials of novel cancer therapies. Key activities include the development of Chimeric Endocrine Receptor T-cell (CER-T) technology, a form of CAR-T therapy, specifically targeting ovarian cancer. Research and development efforts also encompass the creation of immunotherapies and cancer vaccines, including a breast cancer vaccine developed in collaboration with the Cleveland Clinic. The segment utilizes advanced immunological and cellular technologies to target and eliminate cancer cells. Patient impact is addressed through the potential for improved treatment outcomes and reduced side effects compared to traditional therapies. Market positioning is driven by the unmet need for effective cancer treatments, with a competitive advantage in innovative CAR-T and vaccine technologies. Future opportunities include expanding the pipeline to other cancer types and advancing clinical trials. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical studies. Partnerships with research institutions and pharmaceutical companies are crucial for advancing these therapies.

This segment is dedicated to the discovery and development of antiviral drug candidates, with a primary focus on COVID-19. Research and development activities involve identifying and testing compounds that inhibit specific protein functions of the virus. The segment utilizes drug discovery platforms and collaborates with partners like MolGenie GmbH to identify and develop potential drug candidates. The therapeutic area is infectious diseases, specifically targeting COVID-19. The patient impact is aimed at providing effective treatments for viral infections, potentially reducing the severity of illness and improving patient outcomes. Market positioning is based on addressing the ongoing need for antiviral therapies, with a competitive advantage in innovative drug discovery approaches. Future opportunities include expanding the pipeline to other viral diseases and advancing clinical trials. Regulatory and clinical aspects involve navigating regulatory pathways and conducting clinical trials to demonstrate safety and efficacy. Partnerships and collaborations are essential for accelerating drug development and commercialization.